{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:02:26Z","timestamp":1784203346931,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00404-018-4915-1","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T09:12:17Z","timestamp":1537866737000},"page":"873-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Secondary cytoreduction in ovarian cancer: who really benefits?"],"prefix":"10.1007","volume":"298","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-7378","authenticated-orcid":false,"given":"Maria Teresa","family":"Giudice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"D\u2019Indinosante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Cappuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Gallotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"4915_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2018. CA Cancer J Clin 67:7","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"4915_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.1991.9.4.658","volume":"9","author":"PF Conte","year":"1991","unstructured":"Conte PF, Bruzzone M, Carnino F (1991) Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 9(4):658\u2013663","journal-title":"J Clin Oncol"},{"key":"4915_CR3","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496","journal-title":"N Engl J Med"},{"key":"4915_CR4","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"issue":"2","key":"4915_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ygyno.2016.05.017","volume":"142","author":"M Petrillo","year":"2016","unstructured":"Petrillo M, Amadio G, Salutari V et al (2016) Impact of Bevacizumab containing first line chemotherapy in recurrent disease in epithelial ovarian cancer. A case-control study. Gynecol Oncol. 142(2):231\u2013236","journal-title":"A case-control study. Gynecol Oncol."},{"issue":"6","key":"4915_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11912-012-0260-x","volume":"14","author":"P Harter","year":"2012","unstructured":"Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539\u2013543","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"4915_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","volume":"19","author":"WJ Tian","year":"2012","unstructured":"Tian WJ, Chi DS, Sehouli J et al (2012) A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 19(2):597\u2013604","journal-title":"Ann Surg Oncol"},{"key":"4915_CR8","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Ovarian Cancer. Version 1.2017. Available online at http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#ovarian"},{"issue":"1","key":"4915_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ygyno.2014.09.017","volume":"136","author":"CK Lee","year":"2015","unstructured":"Lee CK, Lord S, Grunewald T et al (2015) Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. Gynecol Oncol 136(1):18\u201324","journal-title":"Gynecol Oncol"},{"issue":"9","key":"4915_CR10","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/cncr.21845","volume":"106","author":"DS Chi","year":"2006","unstructured":"Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106(9):1933\u20131939","journal-title":"Cancer"},{"key":"4915_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2407-14-22","volume":"14","author":"R Laar van de","year":"2014","unstructured":"van de Laar R, Zusterzeel PL, Van Gorp T et al (2014) Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomized controlled study. BMC Cancer. 14:22","journal-title":"BMC Cancer."},{"issue":"Suppl","key":"4915_CR12","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","volume":"35","author":"A Du Bois","year":"2017","unstructured":"Du Bois A, Vergote I, Ferron G et al (2017) A randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recur- rent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J Clin Oncol 35(Suppl):5501","journal-title":"J Clin Oncol"},{"issue":"2","key":"4915_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ygyno.2014.05.029","volume":"134","author":"M Petrillo","year":"2014","unstructured":"Petrillo M, Pedone Anchora L, Tortorella L et al (2014) Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. Gynecol Oncol 134(2):257\u2013261","journal-title":"Gynecol Oncol"},{"key":"4915_CR14","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1245\/s10434-015-4523-2","volume":"22","author":"A Musella","year":"2015","unstructured":"Musella A, Marchetti C, Palaia I et al (2015) Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: a Single-Institution Experience. Ann Surg Oncol 22:4211\u20134216","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"4915_CR15","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ejca.2006.03.025","volume":"42","author":"G Ferrandina","year":"2006","unstructured":"Ferrandina G, Legge F, Salutari V et al (2006) Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer 42(14):2296\u20132302","journal-title":"Eur J Cancer"},{"issue":"1","key":"4915_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ygyno.2013.06.020","volume":"131","author":"M Petrillo","year":"2013","unstructured":"Petrillo M, Fagotti A, Ferrandina G et al (2013) Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol 131(1):36\u201341","journal-title":"Gynecol Oncol"},{"issue":"12","key":"4915_CR17","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1245\/s10434-013-3091-6","volume":"20","author":"M Petrillo","year":"2013","unstructured":"Petrillo M, Ferrandina G, Fagotti A et al (2013) Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery versus Neoadjuvant Chemotherapy. Ann Surg Oncol 20(12):3955\u20133960","journal-title":"Ann Surg Oncol"},{"key":"4915_CR18","first-page":"36","volume":"95","author":"Y Luo","year":"2016","unstructured":"Luo Y, Lee M, Kim HS et al (2016) Effect of\u00a0neoadjuvant\u00a0chemotherapy\u00a0on\u00a0platinum\u00a0resistance in stage IIIC and IV epithelial\u00a0ovarian cancer. Medicine 95:36","journal-title":"Medicine"},{"key":"4915_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1245\/s10434-015-4623-z","volume":"22","author":"AA Costa da","year":"2015","unstructured":"da Costa AA, Valadares CV, Baiocchi G et al (2015) Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. Ann Surg Oncol 22:971\u2013978","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"4915_CR20","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, du Bois A, Hahmann M et al (2006) Surgery in Recurrent Ovarian Cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol 13(12):1702\u20131710","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4915_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 21(2):289\u2013295","journal-title":"Int J Gynecol Cancer."},{"key":"4915_CR22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J et al (2015) Standard chemotherapy with or without bevacizumab for woman with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomized trial. Lancet Oncol 16:928\u2013936","journal-title":"Lancet Oncol"},{"key":"4915_CR23","doi-asserted-by":"crossref","unstructured":"Coleman RL, Brady MF, Herzog TJ et al (2015) A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). Presented at: Society of Gynecologic Oncology 2015 annual meeting on women\u2019s cancer; 28\u201331 March, 2015; Chicago, Abstract 3","DOI":"10.1016\/j.ygyno.2015.01.005"},{"issue":"Suppl 3","key":"4915_CR24","doi-asserted-by":"publisher","first-page":"S952","DOI":"10.1245\/s10434-015-4651-8","volume":"22","author":"M Petrillo","year":"2015","unstructured":"Petrillo M, Paris I, Vizzielli G et al (2015) Neoadjuvant Chemotherapy followed by Maintenance Therapy with or without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: a Case-Control Study. Ann Surg Oncol 22(Suppl 3):S952\u2013S958","journal-title":"Ann Surg Oncol"},{"key":"4915_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","volume":"70","author":"R Rouzier","year":"2017","unstructured":"Rouzier R, Gouy S, Selle F et al (2017) Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer 70:133\u2013142","journal-title":"Eur J Cancer"},{"key":"4915_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ygyno.2015.12.033","volume":"141","author":"T Mitamura","year":"2016","unstructured":"Mitamura T, Gourley C, Sood AK (2016) Prediction of anti-angiogenesis escape. Gynecol Oncol 141:80\u201385","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4915_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","volume":"112","author":"RE Bristow","year":"2009","unstructured":"Bristow RE, Puri I, Chi DS et al (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112(1):265\u2013274","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4915_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ygyno.2016.01.027","volume":"141","author":"JM Janco","year":"2016","unstructured":"Janco JM, Kumar A, McGree ME et al (2016) Performance of AGO score for secondary cytoreduction in a high-volume U.S. center. Gynecol Oncol 141(1):140\u2013147","journal-title":"Gynecol Oncol"},{"issue":"2","key":"4915_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","volume":"19","author":"WJ Tian","year":"2012","unstructured":"Tian WJ, Chi DS, Sehouli J et al (2012) A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 19(2):597\u2013604","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4915_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ygyno.2015.02.004","volume":"137","author":"R Laar van de","year":"2015","unstructured":"van de Laar R, Massuger LF, Van Gorp T et al (2015) External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. Gynecol Oncol 137(2):210\u2013215","journal-title":"Gynecol Oncol"},{"issue":"8","key":"4915_CR31","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","volume":"13","author":"A Fagotti","year":"2006","unstructured":"Fagotti A, Ferrandina G, Fanfani F et al (2006) A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 13(8):1156\u20131161","journal-title":"Ann Surg Oncol"},{"issue":"3\u20134","key":"4915_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000159266","volume":"75","author":"A Fagotti","year":"2008","unstructured":"Fagotti A, Fanfani F, Rossitto C et al (2008) A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET\/CT and staging laparoscopy. Oncology. 75(3\u20134):152\u2013158","journal-title":"Oncology."},{"issue":"2","key":"4915_CR33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1245\/s10434-014-4011-0","volume":"22","author":"F Fanfani","year":"2015","unstructured":"Fanfani F, Monterossi G, Fagotti A et al (2015) Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 22(2):649\u2013654","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4915_CR34","first-page":"346","volume":"13","author":"A Hussain","year":"2009","unstructured":"Hussain A, Mahmood H, Singhal T et al (2009) Long-term study of port-site incisional hernia after laparoscopic procedures. JSLS. 13(3):346\u2013349","journal-title":"JSLS."},{"issue":"6","key":"4915_CR35","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s00464-013-3390-9","volume":"28","author":"V Gallotta","year":"2014","unstructured":"Gallotta V, Fagotti A, Fanfani F et al (2014) Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc 28(6):1808\u20131815","journal-title":"Surg Endosc"},{"issue":"2","key":"4915_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ygyno.2013.01.015","volume":"129","author":"JF Magrina","year":"2013","unstructured":"Magrina JF, Cetta RL, Chang YH (2013) Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol 129(2):336\u2013340","journal-title":"Gynecol Oncol"},{"issue":"4","key":"4915_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4293\/108680812X13462882736691","volume":"16","author":"FR Nezhat","year":"2012","unstructured":"Nezhat FR, Denoble SM, Cho JE (2012) Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers. JSLS. 16(4):511\u2013518","journal-title":"JSLS."},{"issue":"2","key":"4915_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ygyno.2017.05.022","volume":"146","author":"AGZ Eriksson","year":"2017","unstructured":"Eriksson AGZ, Graul A, Yu MC (2017) Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: perioperative and oncologic outcomes. Gynecol Oncol 146(2):263\u2013267","journal-title":"Gynecol Oncol"},{"issue":"3","key":"4915_CR39","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.3802\/jgo.2016.27.e24","volume":"27","author":"ES Paik","year":"2016","unstructured":"Paik ES, Lee YY, Kim TJ et al (2016) Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. J Gynecol Oncol. 27(3):e24","journal-title":"J Gynecol Oncol."},{"issue":"4","key":"4915_CR40","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jmig.2017.10.024","volume":"25","author":"V Gallotta","year":"2018","unstructured":"Gallotta V, Conte C, Giudice MT et al (2018) Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: a Large. Single-Institution Experience. J Minim Invasive Gynecol. 25(4):644\u2013650","journal-title":"Single-Institution Experience. J Minim Invasive Gynecol."},{"issue":"2","key":"4915_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ygyno.2014.05.007","volume":"134","author":"PF Escobar","year":"2014","unstructured":"Escobar PF, Levinson KL, Magrina J (2014) Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: a multi-institutional study. Gynecol Oncol 134(2):253\u2013256","journal-title":"Gynecol Oncol"},{"issue":"4","key":"4915_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/IGC.0000000000000664","volume":"26","author":"A Hotouras","year":"2016","unstructured":"Hotouras A, Desai D, Bhan C (2016) Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: a Systematic Literature Review. J Gynecol Cancer. 26(4):661\u2013670","journal-title":"J Gynecol Cancer."},{"issue":"3","key":"4915_CR43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","volume":"136","author":"O Zivanovic","year":"2015","unstructured":"Zivanovic O, Abramian A, Kullmann M (2015) HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 136(3):699\u2013708","journal-title":"Int J Cancer"},{"key":"4915_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Driel van","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K (2018) Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med 378:230\u2013240","journal-title":"N Engl J Med"},{"key":"4915_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2011.04.008","volume":"122","author":"A Fagotti","year":"2011","unstructured":"Fagotti A, Costantini B, Vizzielli G et al (2011) HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol 122:221\u2013225","journal-title":"Gynecol Oncol"},{"issue":"3","key":"4915_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jmig.2014.11.008","volume":"22","author":"A Fagotti","year":"2015","unstructured":"Fagotti A, Costantini B, Gallotta V et al (2015) Minimally invasive secondary cytoreduction plus\u00a0HIPEC\u00a0versus open surgery plus\u00a0HIPEC\u00a0in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes. J Minim Invasive Gynecol. 22(3):428\u2013432","journal-title":"J Minim Invasive Gynecol."},{"issue":"2","key":"4915_CR47","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.canlet.2015.08.028","volume":"369","author":"TV Gorodnova","year":"2015","unstructured":"Gorodnova TV, Sokolenko AP, Ivantsov AO et al (2015) High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. Cancer Lett 369(2):363\u2013367","journal-title":"Cancer Lett"},{"issue":"3","key":"4915_CR48","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ygyno.2015.07.101","volume":"139","author":"H Mahdi","year":"2015","unstructured":"Mahdi H, Gockley A, Esselen K et al (2015) Outcome of neoadjuvant chemotherapy in BRCA1\/2 mutation positive women with advanced-stage M\u00fcllerian cancer. Gynecol Oncol 139(3):407\u2013412","journal-title":"Gynecol Oncol"},{"issue":"3","key":"4915_CR49","doi-asserted-by":"publisher","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","volume":"217","author":"M Petrillo","year":"2017","unstructured":"Petrillo M, Marchetti C, De Leo R et al (2017) BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol 217(3):334.e1\u2013334.e9","journal-title":"Am J Obstet Gynecol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-018-4915-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-018-4915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-018-4915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T18:41:17Z","timestamp":1720636877000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-018-4915-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4915"],"URL":"https:\/\/doi.org\/10.1007\/s00404-018-4915-1","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"assertion":[{"value":"19 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}